Risk Factors Associated with Misuse of Soft Mist Inhaler in Patients with Chronic Obstructive Pulmonary Disease
DOI: https://doi.org/10.2147/copd.s458200
2024-05-31
International Journal of COPD
Abstract:Jong Geol Jang, &ast Young Seok Lee, &ast Kyung Soo Hong, June Hong Ahn Division of Pulmonology and Allergy, Department of Internal Medicine, Yeungnam University Medical Center, Yeungnam University College of Medicine, Daegu, Republic of Korea &astThese authors contributed equally to this work Correspondence: Jong Geol Jang; June Hong Ahn, Division of Pulmonology and Allergy, Department of Internal Medicine, College of Medicine, Yeungnam University and Regional Center for Respiratory Diseases, Yeungnam University Medical Center, 170 Hyeonchung-ro, Namgu, Daegu, 42415, Republic of Korea, Tel +82-53-620-4367 ; +82-53-640-6577, Email ; Purpose: The use of inhaled bronchodilators is the mainstay of treatment for patients with chronic obstructive pulmonary disease (COPD). Although the soft mist inhaler (SMI) was developed to overcome the disadvantages of pressurized metered dose and drug powder inhalers, misuse during handling has been frequently observed in many studies. However, few studies have focused on SMI misuse among patients with COPD. Thus, we aimed to assess and identify the risk factors associated with SMI misuse among patients with COPD. Patient and Methods: In this prospective, observational, cross-sectional study, we enrolled patients with COPD who were undergoing SMI treatment between January 2018 and March 2020. An advanced nurse practitioner assessed the participants' handling of the device by using a check list. Results: Among 159 participants, 136 (85.5%) reported inhaler misuse. Duration of COPD and COPD assessment test (CAT) scores were positively associated with inhaler misuse; adherence and education level were negatively associated with inhaler misuse. In the multivariable analysis, a low educational level (less than high school), high CAT score (≥ 10), and short duration of COPD (≤ 2 years) were identified as risk factors for SMI misuse. Conclusion: SMI misuse remains common among patients with COPD. Therefore, clinicians should pay close attention to their patients using SMIs, especially in the early period after the diagnosis of COPD. Keywords: chronic obstructive pulmonary disease, bronchodilators, misuse, soft mist inhaler Chronic obstructive pulmonary disease (COPD) is a common, progressive disease with persistent respiratory symptoms and airflow limitation. 1 COPD is a major cause of chronic morbidity and mortality and is the third leading cause of death in 2019. 2 Inhaler therapy is the mainstay treatment for patients with COPD; it delivers long-acting bronchodilators to the respiratory tract. Inhaled bronchodilators improve dyspnea, quality of life, and lung function and reduce acute exacerbation in patients with COPD. 1 The most common inhalational devices are the pressurized metered-dose inhaler (pMDI) and the drug powder inhalers (DPI). pMDI require precise coordination between inhalation and hand actuation for effective drug delivery; DPI require strong inhalation power to aerosolize the drug powder. The soft mist inhaler (SMI) is a propellant-free, multi-dose inhaler that does not require no the strong inhalation power. SMI provide slow-moving and long-lasting aerosolization, minimizing error in coordination between hand actuation and inhalation. 3 For effective delivery, correct use of inhaler is essential. Errors in inhaler use are associated with acute exacerbation of COPD 4,5 reduced disease control, 6 and increased economic burden. 7 Previous studies have reported that misuse of pMDI and DPI is common in clinical practice. 5,8,9 Although many studies have investigated the error rates and factors associated with misuse, there are still some limitations; 1) they included participants using different devices (including SMI); 2) they included both COPD and asthma patients, 6,7,9–11 therefore have not focused on SMI misuse in patients with COPD. As a result, the risk factors associated with SMI misuse in patients with COPD are not well established. Although one study investigated SMI misuse in patients with COPD, it included a small number of participants, 12 thereby the risk factors associated with SMI misuse remain unclear. Therefore, the aim of this study was to evaluate the error rate and identify risk factors associated with SMI misuse in patients with COPD who were using only SMI. This prospective, cross-sectional, and observational study included patients who were recruited from a tertiary hospital in South Korea. The patients were enrolled between January 2018 and March 2020. Inclusion criteria were as follows: 1) patients who were aged > 40 years with a diagnosis of COPD according to the Global Initiative for Chronic Obstructive Lung Dis -Abstract Truncated-
respiratory system